Comparison of Prohance With Gadovist /Gadavist in Magnetic Resonance Imaging (MRI) of the Brain

This study aims at a direct comparison between PROHANCE (0.1 mmol/kg) and a validated
comparator GADOVIST/GADAVIST (0.1 mmol/kg) in a crossover intra-individual design in
subjects with brain tumors to confirm the identical overall technical and diagnostic
performance of the two MR contrast agents.

Clinical Trial Conditions: Brain Disease

Treatments in this Clinical Trial : Gadoteridol, gadobutrol

Clinical Trial Phase: Phase 4

Eligible Clinical Trial Participant Age : Between 18 years to 100 years

Can Healthy Volunteers Participate: No

Clinical Trial Lead Sponsor: Bracco Diagnostics, Inc

Detailed Clinical Trial Description: This study aims at a direct comparison between PROHANCE (0.1 mmol/kg) and a validated
comparator GADOVIST/GADAVIST (0.1 mmol/kg) in a crossover intra-individual design in
subjects with brain tumors to confirm the identical overall technical and diagnostic
performance of the two MR contrast agents.

The clinical trial information was obtained from http://clinicaltrials.gov/ct2/show/NCT01613417